Clinical trials · Texas
Aggression clinical trials in Texas
We’re tracking 15 recruiting aggression studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT06609330Recruiting
Anger and aggression help after military betrayal
This study offers a program to help people who feel angry and have acted aggressively after a betrayal during military service. It aims to reduce anger and aggression so you can feel better and improve your relationships.
Fort Cavazos, TexasAges 18 years+ - NCT04793776Recruiting
MERA program to reduce aggression in PTSD
This trial tests a program called MERA to help people with PTSD-related symptoms manage emotions and reduce aggressive outbursts. It’s meant for Veterans who’ve had recent impulsive aggression and may benefit from structured skills practice and coaching.
Houston, TexasAges 18–64 - NCT05475925RecruitingPhase 1/Phase 2
Test drug DR-01 for specific blood cancer types
This early-phase study tests DR-01 to treat large granular lymphocytic leukemia (LGLL) or certain aggressive T-cell or cytotoxic lymphomas. It aims to see whether the drug is safe and can shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Houston, TexasAges Any age - NCT07156565RecruitingPhase 1
Study of actinium therapy for advanced soft tissue sarcoma
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
Houston, TexasAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Houston, TexasAges 18 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Dallas, TexasAges 18 years+ - NCT05685173RecruitingPhase 1
Study safety of REGN5837 with odronextamab in adult B-cell lymphoma
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
Dallas, TexasAges 18 years+ - NCT04472338Recruiting
Prostate cancer screening for people with higher genetic risk
This study looks at prostate cancer screening for people who may be at higher risk because of a specific inherited (genetic) change. It may help your care team find the best screening approach to catch aggressive prostate cancer earlier.
San Antonio, TexasAges 40 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Houston, TexasAges 18 years+ - NCT05543681RecruitingPhase 2
Study drug for agitation in Alzheimer’s dementia with caregiver support
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
Austin, TexasAges 60 years+ - NCT06085729RecruitingPhase 1/Phase 2
Study of ADI-PEG20 with chemo for aggressive prostate cancer
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
San Antonio, TexasAges birth–18 years - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Temple, TexasAges 18 years+ - NCT07162480RecruitingPhase 2
New drug for aggressive adenoid cystic carcinoma
This trial tests a new drug called Puxitatug Samrotecan (AZD8205) for people with an aggressive form of adenoid cystic carcinoma. It aims to see if the drug can shrink tumors or slow the disease in patients whose cancer has advanced or spread.
Houston, TexasAges 18 years+
Where these studies are running in Texas
Institutions with a site for the recruiting aggression studies listed above.
- The University of Texas MD Anderson Cancer Center · 6 studies
- Baylor Scott & White Health
- Baylor Scott & White Research Institute
- Baylor University Medical Center
- Carl R. Darnall Army Medical Center
- Dren Investigational Site
- Kerwin Medical Center
- Methodist Healthcare System of San Antonio
What taking part in a aggression study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Aggression trials in other states
Common questions
- Are there aggression clinical trials in Texas?
- Yes. We're currently tracking 15 recruiting aggression studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a aggression study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a aggression trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New aggression studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.